Targeting Tumors: How AstraZeneca (AZN) is Transforming Precision Medicine

AstraZeneca (AZN) is aiming to redefine cancer care by shifting the focus from late-stage interventions to early-line precision medicine. Dave Fredrickson, EVP of Oncology Business at AstraZeneca, discusses the company's aggressive strategy to replace traditional chemotherapy with targeted treatments that minimize side effects. Looking ahead, the conversation highlights recent regulatory milestones and the transformative potential of cell therapy to dramatically improve patient outcomes.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about